Glenmark Shares Soar 3% on Approval to Start Phase 3 Trial
September 5, 2025September 5, 2025 Shares of Glenmark Pharmaceuticals Ltd soared 3% on Friday, 4 September, after the company announced securing approval from DCGI. Glenmark Pharmaceuticals’ shares surged after the Drugs Controller General of India (DCGI) approved a Phase 3 clinical trial of Envafolimab, a new subcutaneous PD-L1 inhibitor,…